Once again, fueled by booming sales of their GLP-1 products, Eli Lilly and Novo Nordisk were the top performers in the biopharma industry in the second quarter. But there was a better story afoot in the aggregate as drugmakers revealed their second-quarter financials.
The period saw a consistent surge in sales throughout the sector. Of the top 25 drugmakers, nine had double-digit increases year over year, and nine more companies saw sales increases of between 6% and 9% in the second quarter.
